Absence of interaction between oxcarbazepine and erythromycin
- 1 August 1992
- journal article
- clinical trial
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 86 (2), 120-123
- https://doi.org/10.1111/j.1600-0404.1992.tb05051.x
Abstract
When erythromycin (ERY) is co-administrated with the antiepileptic carbamazepine (CBZ), a drug interaction may cause an increase in CBZ plasma concentrations, which can result in CBZ related toxic symptoms. This cross-over study was designated to investigate whether ERY influences the pharmacokinetics of the new antiepileptic oxcarbazepine (OXC) and its metabolites. In 8 healthy volunteers there were no significant differences in AUC, peak plasma concentrations or time to peak concentration when OXC was administered either with or without ERY. The results of this study suggest that OXC may offer an important advantage over CBZ especially when concomitant therapy with ERY is required.Keywords
This publication has 7 references indexed in Scilit:
- Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects.British Journal of Clinical Pharmacology, 1991
- Clinically Relevant Anti-Epileptic Drug InteractionsJournal of International Medical Research, 1990
- Metabolic Characteristics of Oxcarbazepine (®Trileptal) and their Beneficial Implications for Enzyme Induction and Drug InteractionsBehavioural Neurology, 1990
- Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11‐epoxide metabolite.British Journal of Clinical Pharmacology, 1987
- Severe carbamazepine intoxication after coadministration of erythromycinThe Journal of Pediatrics, 1986
- The metabolism of14C-oxcarbazepine in manXenobiotica, 1986
- Carbamazepine Metabolism in ManClinical Pharmacokinetics, 1985